Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absent, advertising, Alexander, allocated, behalf, broker, Brookline, buy, Certificate, CIM, constitute, dealer, di, Division, FINRA, LLC, LP, promulgated, qualification, unlawful
Removed:
account, advance, Black, breach, brought, civil, compel, controlled, Court, defamation, Delaware, dismissed, dispute, District, Eastern, emotional, end, infliction, informed, intact, lawsuit, motion, partially, pendency, Pennsylvania, plausible, prejudice, questionable, reinstate, Ruling, sought, sued, wrongful
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 3.1 Certificate of Amendment to Relmada Therapeutics, Inc. Articles of Incorporation, Dated April 12, 2019
- 4.1 Form of Warrant
- 10.1 Amendment No. 4 to the Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, As Amended
- 10.2 Form of Unit Purchase Agreement
- 10.3 Form of Subscription Agreement
- 10.4 Form of Registration Rights Agreement
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
RLMD similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Relmada Therapeutics, Inc. (the “Company”) on Form 10-Q for the three months ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sergio Traversa, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Quarterly Report fairly presents, in all material respects, the consolidated financial condition and results of consolidated operations of the Company. |
Relmada Therapeutics, Inc. | ||
By: | /s/ Sergio Traversa | |
Sergio Traversa | ||
Chief Executive Officer (Principal Executive Officer) |
May 14, 2019